The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

We have extended our partnership with BeOne Medicines and BeOne Care Foundation to provide access to treatment for chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively by the end of 2028. Read the full press release.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • My PCR Releases New Resource on Treatment Free Remission (TFR)

    My PCR Releases New Resource on Treatment Free Remission (TFR)

    My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).

  • Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

    Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

    The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!

  • Novartis, The Max Foundation, and a young girl who dreamed to be a lawyer

    Novartis, The Max Foundation, and a young girl who dreamed to be a lawyer

    The Max Foundation and Novartis renew their commitment to CML patients